Merck (MRK) reported third-quarter revenue and profit that both beat expectations, driven mainly by procurement timing effects and the steady volume ramp of Keytruda, but the timing factor may pull forward subsequent performance, and the transition of Keytruda to a subcutaneous formulation as well as generic competition also warrant continued tracking.
Merck’s third-quarter sales rose 5% to more than $18 billion, and non-GAAP net profit, though down 4%, was still close to $6.2 billion. Both figures easily exceeded analysts’ consensus expectations, and management’s full-year 2026 revenue and profit guidance also came in above expectations. The stock rose more than 2% as a result, while the S&P 500 fell 1.8%.
Several experts covering Merck quickly raised their target prices, and exactly half of the “Big Four” U.S. banks did so. Jason Gerberry of BofA Securities (BAC) raised his target price to $165 per share from $163, while Chris Schott of J.P. Morgan (JPM) raised his to $175 from $165, with both maintaining “Buy” ratings.
However, about $550 million of the growth came from changes in customer procurement timing, and excluding this factor, sales were barely higher. Encouragingly, the volume ramp of Keytruda Qlex injection and Winrevair was enough to offset losses suffered by older drugs from generic competition: Winrevair sales were $694 million, up 93% year over year, and Keytruda Qlex sales were $830 million, higher than $463 million in the previous quarter.
Procurement timing often manifests as softer performance in subsequent quarters. After Januvia and Bridion lost U.S. exclusivity, generics are eroding sales of these two products, with Bridion sales down 67%. Keytruda’s 6% growth masked a transition: sales of the intravenous version declined as patients shifted to the subcutaneous Qlex, which Merck is counting on to protect the franchise after Keytruda’s main U.S. patent expires in 2028 through its separate patent. Profit fell because expenses grew faster than sales, as the company increased launch promotion and R&D investment and interest expense rose, while a lower tax rate cushioned the impact, with its non-GAAP tax rate guidance lowered to 32% to 33% from 35% to 36%. Going forward, it is necessary to watch whether fourth-quarter sales give back the benefit brought by the timing factor, and to track Qlex’s share of Keytruda sales, which is currently close to 10%.
Merck owns a series of generally robust blockbuster drugs, led by Keytruda, and has a fairly active R&D pipeline that could add another major drug. Its forward valuation is basically in line with other pharmaceutical companies, and it pays a relatively generous dividend, currently yielding 2.3%, and is regarded as a solid investment target in the healthcare sector with room for modest growth and also a good income stock.